TESARO weakness a buying opportunity, says Mizuho Mizuho believes TESARO weakness following missed secondary endpoints in Ph. III rolapitant trials is an over-reaction and a buying opportunity. The analyst does not believe the missed secondary endpoints are a major focus of physicians or product success.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.